期刊
FRONTIERS IN CELLULAR NEUROSCIENCE
卷 15, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fncel.2021.705618
关键词
neuroinflammation; HLA-DR; HLA-G; PD-L1; neurofilament light chain; cerebrospinal fluid
资金
- Sao Paulo Research Foundation (FAPESP) [2014/26431-0, 2013/00837-8, 2012/09879-2]
- National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM) [465489/2014-1]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brazil (CAPES) [001]
The study found that NTZ treatment significantly decreased NfL levels in CSF of MS patients, increased sHLA-G levels in serum, and enhanced tolerogenic and migratory functions of pDCs in peripheral blood.
Background Neurofilament Light (NfL) chain levels in both cerebrospinal fluid (CSF) and serum have been correlated with the reduction of axonal damage in multiple sclerosis (MS) patients treated with Natalizumab (NTZ). However, little is known about the function of plasmacytoid cells in NTZ-treated MS patients. Objective To evaluate CSF NfL, serum levels of soluble-HLA-G (sHLA-G), and eventual tolerogenic behavior of plasmacytoid dendritic cells (pDCs) in MS patients during NTZ treatment. Methods CSF NfL and serum sHLA-G levels were measured using an ELISA assay, while pDCs (BDCA-2(+)) were accessed through flow cytometry analyses. Results CSF levels of NfL were significantly reduced during NTZ treatment, while the serum levels of sHLA-G were increased. Moreover, NTZ treatment enhanced tolerogenic (HLA-G(+), CD274(+), and HLA-DR+) molecules and migratory (CCR7(+)) functions of pDCs in the peripheral blood. Conclusion These findings suggest that NTZ stimulates the production of molecules with immunoregulatory function such as HLA-G and CD274 programmed death-ligand 1 (PD-L1) which may contribute to the reduction of axonal damage represented by the decrease of NfL levels in patients with MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据